Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global chemotherapy-induced neutropenia treatment market size was estimated at USD 1.63 billion in 2024 and is projected to decline at a CAGR of -0.48% from 2025 to 2030. The market is projected to be declining due to regulatory pressures and pricing constraints in key markets are also impacting on the overall market value, as governments and healthcare systems push for cost-effective treatment alternatives. Despite the expected decline, several opportunities exist within the chemotherapy-induced neutropenia (CIN) treatment market. The continuous development of novel long-acting G-CSFs and next-generation biologics presents a significant growth avenue, as these innovations can enhance treatment efficacy and patient compliance.

The increasing global burden of cancer is a major driver of the chemotherapy-induced neutropenia (CIN) treatment industry. Cancer remains one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed annually. According  to the American Cancer Society, approximately 1.96 million new cancer cases and 609,820 cancer-related deaths are expected in the U.S. in 2023 alone. As a result, the pharmaceutical and healthcare industries are witnessing an increasing demand for cancer treatments, diagnostic tools, and therapies. Chemotherapy continues to be a cornerstone of cancer treatment, often used alone or in combination with surgery, radiation therapy, or targeted therapies.

The pharmaceutical sector has responded to the growing CIN challenge with significant advancements in granulocyte colony-stimulating factors (G-CSFs) and other supportive care therapies. Key players in the CIN treatment market, such as Amgen, Mylan, and Coherus BioSciences, have developed biosimilars and novel Distribution Channels of filgrastim (Neupogen) and pegfilgrastim (Neulasta) to mitigate chemotherapy-induced neutropenia. These biologics stimulate neutrophil production, reducing infection risk and enabling patients to maintain optimal chemotherapy schedules and improve quality life of cancer patients.

Furthermore, prophylactic antibiotics are increasingly being also used to prevent infections in high-risk CIN patients, particularly those undergoing intensive chemotherapy for hematologic malignancies. The growing preference for fluoroquinolones, beta-lactams, and macrolides as preventive agents is driven by their efficacy in reducing febrile neutropenia episodes. Additionally, advances in antibiotic stewardship programs and guidelines from organizations like the Infectious Diseases Society of America (IDSA) and the European Society for Medical Oncology (ESMO) have supported the rational use of prophylactic antibiotics, further bolstering market growth.

Moreover, the CIN treatment market is evolving with the growing adoption of biosimilars, driven by regulatory approvals, innovative drug delivery systems, competitive pricing, and strategic market expansion. In April 2024 , the FDA introduced the Biosimilars Action Plan (BAP) to foster innovation and competition in the biological products market, particularly by facilitating the development and approval of biosimilars and interchangeable biosimilars. The plan focuses on improving the efficiency of the biosimilar approval process, enhancing scientific and regulatory clarity, promoting effective communication to increase understanding, and supporting biosimilar adoption while addressing misinformation and anticompetitive behaviors. This initiative is expected to significantly impact the Chemotherapy-Induced Neutropenia (CIN) treatment industry by accelerating the availability of biosimilar granulocyte colony-stimulating factors (G-CSFs), such as filgrastim and pegfilgrastim.

Market Concentration & Characteristics

The CIN treatment market is advancing with innovations in biologic therapies, including long-acting Distribution Channels and novel recombinant growth factors. Newer drugs such as pegfilgrastim and lipegfilgrastim enhance treatment efficacy while reducing administration frequency. The rise of biosimilars is improving accessibility and affordability. Advanced drug delivery mechanisms and combination therapies are driving the next wave of breakthroughs.

Mergers and acquisitions are shaping the CIN treatment landscape, with pharmaceutical companies acquiring biotech firms to strengthen their biologic portfolios. Strategic partnerships are fostering innovations in granulocyte transfusions, immunomodulatory agents, and prophylactic antibiotics. Companies are expanding biomanufacturing capabilities and accelerating clinical trials to gain a competitive edge. The demand for biosimilars and cost-effective biologics is driving market consolidation.

Regulatory agencies like the FDA and EMA enforce strict guidelines to ensure the safety and efficacy of CIN treatments. The approval process for growth factors, antibiotics, and antifungal agents involves rigorous clinical evaluations, impacting market entry timelines. Pricing regulations and reimbursement policies influence the adoption of high-cost biologics. Global regulatory harmonization is essential to streamline approvals and improve patient access.

CIN treatments compete with small-molecule drugs, conventional therapies, and non-pharmacological interventions. While antibiotics and antifungal agents play a crucial role in managing infections, biologics such as G-CSFs and GM-CSFs offer superior efficacy. Granulocyte transfusions and immunomodulatory agents are emerging as adjunct therapies for severe neutropenia. Despite alternatives, biological growth factors remain the standard of care.

The CIN treatment market is growing in Asia-Pacific, Latin America, and the Middle East due to increasing cancer prevalence and improved healthcare infrastructure. Government support for bio manufacturing and expanding insurance coverage are enhancing market penetration. However, pricing pressures, supply chain challenges, and regulatory disparities hinder seamless expansion. Strengthening distribution networks through hospital, retail, and online pharmacies is key to improving accessibility.

Pipeline Analysis

The chemotherapy-induced neutropenia (CIN) treatments sector saw major breakthroughs, particularly in treatments.

• BeyondSpring Inc.’s plinabulin (Plin) (NCT02504489): In three independent randomized studies, Plin demonstrated superior efficacy in treating Chemotherapy-Induced Neutropenia (CIN) and showed a significant clinical benefit in reducing infection rates compared to placebo.

• Enzychem Lifesciences Corporation’s EC-18 (Mosedipimod) (NCT03200340): The world's first oral medicine candidate for the prevention and treatment of Chemotherapy-Induced Neutropenia (CIN) is set to begin dosing its first patient at Asan Medical Center in Seoul, Korea.

Treatment Insights

The growth factors segment dominated the market with an 87.10% share in 2024. Growth factors, such as Granulocyte Colony-Stimulating Factors (G-CSFs), are widely used to prevent and treat neutropenia in cancer patients undergoing chemotherapy. The segment's dominance is attributable to its proven efficacy, widespread adoption in cancer treatment protocols, and continuous advancements in biosimilars. Leading pharmaceutical companies, including Amgen Inc., Evive Biotech, and Sandoz, continue to enhance their product portfolios, strengthening the segment’s market position. In May 2023 , Evive Biotech announced that China’s National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for Ryzneuta for the prevention and treatment of Chemotherapy-Induced Neutropenia (CIN). It stimulates the production and differentiation of neutrophils, thereby reducing the incidence of infection in patients undergoing chemotherapy.

Antibiotic is second largest segment in market, fueled by increasing demand for CIN treatment in cancer patients who are on chemotherapy treatment. It plays a crucial role in the market, driven by the rising incidence of cancer and the increasing adoption of chemotherapy as a primary treatment modality. Since chemotherapy suppresses bone marrow function, leading to a significant reduction in neutrophil count, patients become highly susceptible to bacterial infections. This has fueled the demand for antibiotics, both as a prophylactic measure and a therapeutic intervention, to mitigate infection risks and improve patient outcomes

Drug Insights

The biosimilars segment was the largest and the fastest-growing segment, with a 51.34% revenue share, driven by increasing regulatory approvals, cost-effectiveness, and growing adoption by healthcare providers. Biosimilars of G-CSF drugs, such as filgrastim and pegfilgrastim, have gained prominence due to their comparable efficacy and lower cost than reference biologics. For instance, in February 2025, Kashiv BioSciences, LLC announced that Health Canada granted marketing authorization for its Pegfilgrastim Injection, paving the way for its commercial launch in Canada. This milestone aligns with Kashiv’s strategy to expand access to high-quality biosimilar in global markets for CIN treatment.

In contrast, branded drugs are witnessing a decline in market share due to biosimilar competition and cost-containment measures in healthcare systems worldwide. Despite pricing pressures and healthcare cost concerns, brand loyalty, robust clinical trial data, and physician trust in established drugs continue to drive market growth. Leading pharmaceutical players are focusing on expanding their global footprint through strategic partnerships and product innovations. As cancer rates continue to rise worldwide, the demand for effective CIN management solutions remains high, ensuring sustained growth for the branded drug segment in both developed and emerging markets.

Route of Administration Insights

Parenteral administration led the market, with an 93.36% share in 2024, given the nature of Chemotherapy-Induced Neutropenia (CIN) Treatments requiring systemic absorption. Injectable Distribution Channels, particularly intravenous and subcutaneous G-CSFs, remain the primary mode of administration due to the rapid onset of their action and higher bioavailability compared to oral alternatives. The convenience and efficacy of parenteral drugs continue to drive their widespread use in CIN treatment

Oral emerged as the second-largest route, driven by increasing demand for non-invasive and patient-friendly treatment options. Unlike injectable therapies, oral drugs offer greater convenience, improved patient compliance, and reduced healthcare costs by minimizing the need for hospital visits. The shift towards oral Distribution Channels aligns with the growing emphasis on at-home cancer care, particularly as healthcare systems aim to enhance patient-centric treatment approaches. Additionally, advancements in drug Distribution Channels have led to the development of small-molecule therapies that effectively stimulate neutrophil production and mitigate infection risks.

Distribution Channel Insights

The hospital pharmacies segment held the largest market share of 62.62% in 2024, driven by the high volume of chemotherapy conducted in hospital settings. Hospital pharmacies are the primary source of CIN treatment drugs, ensuring immediate availability and administration of critical medications. A study published in The Lancet Oncology predicts a 53% rise in chemotherapy patients globally, from 9.8 million in 2018 to 15 million by 2040, with 67% of cases in low- and middle-income countries. This surge will significantly impact hospital pharmacies, increasing the demand for CIN treatments such as antibiotics, antifungal agents, and granulocyte colony-stimulating factors (G-CSFs). Hospital pharmacies will be vital in ensuring timely access to these treatments, necessitating expanded infrastructure, workforce training, and cost-effective biosimilars to meet the growing patient needs

Meanwhile, the online pharmacies segment is anticipated to be the fastest-growing due to the increasing trend of e-commerce in the healthcare industry, improved access to prescription drugs, and growing patient preference for home delivery services. Moreover, the growing penetration of e-commerce in the healthcare sector, supported by regulatory frameworks allowing the sale of prescription drugs online, is enhancing market growth. Competitive pricing, discounts, and subscription-based medication models further drive patient preference for online pharmacies.

Regional Insights

North America remains the largest Chemotherapy-Induced Neutropenia (CIN) treatment market with revenue share of 39.27% in 2024, driven by the high prevalence of cancer and widespread use of chemotherapy. However, the market is experiencing a declining trajectory due to several key factors. The increased adoption of targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs) which have lower incidences of neutropenia-has reduced the demand for traditional CIN treatments such as granulocyte colony-stimulating factors (G-CSFs).

U.S. Chemotherapy-induced Neutropenia Treatment Market Trends

The U.S. leads the North American market, supported by strong biopharma investments, early regulatory approvals, and a well-developed biotechnology industry. However, the market is now experiencing a decline due to shifting treatment paradigms, increasing adoption of targeted therapies and immunotherapies, and the growing impact of biosimilar competition.

Europe Chemotherapy-induced Neutropenia Treatment Market Trends

The chemotherapy-induced neutropenia (CIN) treatment market in Europe has traditionally been driven by strong pharmaceutical research and innovation, but the market is now facing increasing cost pressures and shifting treatment trends that could moderate its growth. While Europe's well-established pharmaceutical manufacturing base, supported by state-of-the-art technologies and substantial R&D investments, has positioned the region as a key player in CIN treatment, the rise of biosimilars and alternative cancer therapies is reshaping market dynamics.

The UK chemotherapy-induced neutropenia (CIN) treatment market is undergoing significant changes due to shifting healthcare expenditure patterns, regulatory developments, and evolving pharmaceutical investment trends.

The Germany CIN treatment market, historically driven by a strong pharmaceutical sector, well-developed healthcare infrastructure, and high cancer prevalence, is now facing market saturation and declining growth potential due to shifting treatment approaches, biosimilar pricing pressures, and evolving oncology care strategies.

The France CIN treatment market, while historically competitive and innovation-driven, is now facing increasing pricing pressures, biosimilar-driven revenue declines, and shifting treatment approaches that are reshaping its trajectory. While major pharmaceutical players such as Amgen, Sandoz, Mundipharma, and Cinfa Biotech continue to compete in both reference biologics and biosimilars, the intensified focus on cost containment and regulatory interventions is reducing growth opportunities for traditional CIN treatments.

Asia-Pacific Chemotherapy-induced Neutropenia Treatment Market Trends

The Asia Pacific CIN treatment market, while historically driven by rising cancer prevalence and expanding healthcare infrastructure, is now facing growing challenges due to pricing pressures, biosimilar competition, and evolving treatment paradigms that could moderate its growth. Additionally, while market participants continue investing in the region, they face regulatory complexities, healthcare budget constraints, and uneven treatment access across diverse healthcare systems, limiting broad market expansion.

The Japan CIN treatment market, while traditionally driven by high cancer prevalence and strong healthcare infrastructure, is now encountering increasing pricing pressures, biosimilar-driven market shifts, and evolving oncology treatment paradigms that could moderate its long-term growth.

The China CIN treatment market, while historically driven by a rapidly expanding oncology sector, a strong pharmaceutical industry, and increasing cancer prevalence, is now facing growing pricing pressures, regulatory challenges, and intensified competition that could moderate its long-term growth.

Latin America Chemotherapy-induced Neutropenia Treatment Market Trends

The CIN treatment market in Latin America, while showing moderate growth, faces significant challenges related to healthcare disparities, economic constraints, and evolving treatment trends that could impact its long-term expansion. Although cancer incidence is rising, and access to oncology treatments is improving, healthcare infrastructure remains uneven across the region, leading to gaps in CIN treatment accessibility, particularly in rural areas.

The CIN treatment market in Brazil, while experiencing steady growth, is increasingly shaped by economic challenges, healthcare disparities, and evolving treatment trends that could impact its long-term expansion. Although rising cancer rates and improved healthcare access have fueled demand for granulocyte colony-stimulating factors (G-CSFs) and supportive care therapies, regional inequalities in healthcare infrastructure and limited government funding create barriers to widespread treatment adoption.

Middle East & Africa Chemotherapy-induced Neutropenia Treatment Market Trends

The CIN treatment market in the Middle East and Africa (MEA) region is witnessing moderate growth, driven by increasing cancer cases and improvements in healthcare services. However, the market is diverse, with significant variations in CIN treatment availability and infrastructure across different countries in the region.

The CIN treatment market in Saudi Arabia is experiencing steady growth. This growth is primarily driven by the rising incidence of cancer and an increasing number of chemotherapy treatments in the country. As Saudi Arabia’s healthcare sector continues to develop, the demand for CIN treatments is also rising, supported by better access to advanced medical care, particularly in urban areas with well-established healthcare infrastructure.

Key Chemotherapy-induced Neutropenia Treatment Company Insights

Some key players operating in the global market are Amgen Inc., Sandoz, Coherus BioSciences, Biocon Biologics Inc., Pfizer Inc., Evive Biotech, G1 Therapeutics, Inc. Chemotherapy-Induced Neutropenia (CIN) treatment industry and drug development companies are constantly focusing on developing & upgrading existing technologies to enhance patient outcomes and significantly increase healthcare effectiveness and efficiency.

Recent Developments

• In November 2024, Evive Biotech (Evive) and APOGEPHA Arzneimittel GmbH (APOGEPHA) announced the availability of Ryzneuta in the German market as of October 7, 2024.

• In February 2024, Coherus BioSciences, Inc. successfully launched UDENYCA ONBODY, the company's on-body injector (OBI) presentation of UDENYCA (pegfilgrastim-cbqv). The launch is progressing well, with nationwide distribution and strong adoption by healthcare providers.

• In December 2024, Coherus BioSciences, Inc. announced that it had signed an asset purchase agreement with Intas Pharmaceuticals Ltd. on December 2, 2024, to divest its UDENYCA (pegfilgrastim-cbqv) franchise for up to USD 558.4 million.

Chemotherapy-induced Neutropenia Treatment Market Report Scope

Global Chemotherapy-induced Neutropenia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global chemotherapy-induced neutropenia treatment market report based on treatment, drug, route of administration, distribution channel, and region:

• Treatment Outlook (Revenue, USD Million; 2018 - 2030)

  • Growth Factors

  • Antibiotics

  • Antifungal Agents

  • Other Treatments

• Drug Outlook (Revenue, USD Million; 2018 - 2030)

  • Branded Drugs

  • Biosimilars

• Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

  • Parenteral

  • Oral

• Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait